↓ Skip to main content

S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial

Overview of attention for article published in BMC Cancer, December 2013
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
22 Mendeley
Title
S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial
Published in
BMC Cancer, December 2013
DOI 10.1186/1471-2407-13-583
Pubmed ID
Authors

Yong Wha Moon, Soohyeon Lee, Byeong-Woo Park, Eun-Kyung Kim, Seung Il Kim, Ja Seung Koo, Seho Park, Min Jung Kim, Hyun Cheol Chung, Joo-Hang Kim, Joohyuk Sohn

Abstract

This study evaluated the efficacy and safety of S-1 combined with docetaxel (SD) following doxorubicin plus cyclophosphamide (AC) as neoadjuvant therapy in patients with HER2-negative, stage II-III breast cancer.

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Ecuador 2 9%
United States 1 5%
Unknown 19 86%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 5 23%
Researcher 5 23%
Student > Ph. D. Student 4 18%
Professor > Associate Professor 2 9%
Unspecified 1 5%
Other 4 18%
Unknown 1 5%
Readers by discipline Count As %
Medicine and Dentistry 13 59%
Agricultural and Biological Sciences 3 14%
Nursing and Health Professions 2 9%
Biochemistry, Genetics and Molecular Biology 1 5%
Unspecified 1 5%
Other 0 0%
Unknown 2 9%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 December 2013.
All research outputs
#2,901,747
of 3,628,883 outputs
Outputs from BMC Cancer
#1,394
of 1,786 outputs
Outputs of similar age
#87,958
of 112,461 outputs
Outputs of similar age from BMC Cancer
#71
of 98 outputs
Altmetric has tracked 3,628,883 research outputs across all sources so far. This one is in the 2nd percentile – i.e., 2% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,786 research outputs from this source. They receive a mean Attention Score of 2.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 112,461 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.